Sadeer G Al-Kindi1, Guilherme H Oliveira1. 1. Sadeer G Al-Kindi, Guilherme H Oliveira, Onco-Cardiology Center, University Hospitals Seidman Cancer Center and Harrington Heart and Vascular Institute, Cleveland, OH 44106, United States.
Abstract
AIM: To describe the incidence of cardiovascular mortality (CVM) in survivors of major cancers and identify its trends over the past two decades. METHODS: We used the surveillance, epidemiology and end-results 19 registry to identify young adults (20-49 years), diagnosed with the following major primary cancers: Lung, breast, liver/intrahepatic bile duct, pancreas, prostate, colorectal, and ovarian from 1990 through 2012 and identified the cumulative incidence of CVM after adjusting for confounding factors. RESULTS: We identified a total of 301923 cancers (breast 173748, lung 38938, colorectal 31722, prostate 22848, ovary 16065, liver 9444, pancreas 9158). A total of 2297 (0.8%) of patients had incident CVM. Lung (10-year cumulative CVM 2.4%) and liver (1.73%) cancers had the highest incidence of CVM, while breast (0.6%) and prostate (1.2%) had the lowest CVM mortality, even after multiple adjustments (P < 0.001). Overall, there was a significant improvement in CVM since 1990 [2005-2012 vs 1990-1994, adjusted HR 0.63 (0.54-0.72), P < 0.001]. This was driven by improvements in CVM in lung cancers (P = 0.02), breast (P < 0.001), and a trend in ovarian cancer (P = 0.097). There was no statistically significant improvement in CVM among survivors of colorectal, pancreatic, liver, or prostate cancers. CONCLUSION: The risk of CVM differs among different cancers, and is highest among survivors of lung and liver cancers. The incidence of CVM has decreased over the past 2 decades mainly among survivors of lung and breast cancers.
AIM: To describe the incidence of cardiovascular mortality (CVM) in survivors of major cancers and identify its trends over the past two decades. METHODS: We used the surveillance, epidemiology and end-results 19 registry to identify young adults (20-49 years), diagnosed with the following major primary cancers: Lung, breast, liver/intrahepatic bile duct, pancreas, prostate, colorectal, and ovarian from 1990 through 2012 and identified the cumulative incidence of CVM after adjusting for confounding factors. RESULTS: We identified a total of 301923 cancers (breast 173748, lung 38938, colorectal 31722, prostate 22848, ovary 16065, liver 9444, pancreas 9158). A total of 2297 (0.8%) of patients had incident CVM. Lung (10-year cumulative CVM 2.4%) and liver (1.73%) cancers had the highest incidence of CVM, while breast (0.6%) and prostate (1.2%) had the lowest CVM mortality, even after multiple adjustments (P < 0.001). Overall, there was a significant improvement in CVM since 1990 [2005-2012 vs 1990-1994, adjusted HR 0.63 (0.54-0.72), P < 0.001]. This was driven by improvements in CVM in lung cancers (P = 0.02), breast (P < 0.001), and a trend in ovarian cancer (P = 0.097). There was no statistically significant improvement in CVM among survivors of colorectal, pancreatic, liver, or prostate cancers. CONCLUSION: The risk of CVM differs among different cancers, and is highest among survivors of lung and liver cancers. The incidence of CVM has decreased over the past 2 decades mainly among survivors of lung and breast cancers.
Entities:
Keywords:
Cancer; Cardiovascular disease; Cardiovascular mortality; Trends; Type of cancer
Authors: Berthe M P Aleman; Alexandra W van den Belt-Dusebout; Marie L De Bruin; Mars B van 't Veer; Margreet H A Baaijens; Jan Paul de Boer; Augustinus A M Hart; Willem J Klokman; Marianne A Kuenen; Gabey M Ouwens; Harry Bartelink; Flora E van Leeuwen Journal: Blood Date: 2006-11-21 Impact factor: 22.113
Authors: Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; William B Borden; Dawn M Bravata; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; David Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Graham Nichol; Nina P Paynter; Pamela J Schreiner; Paul D Sorlie; Joel Stein; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner Journal: Circulation Date: 2012-12-12 Impact factor: 29.690
Authors: Kathryn E Weaver; Randi E Foraker; Catherine M Alfano; Julia H Rowland; Neeraj K Arora; Keith M Bellizzi; Ann S Hamilton; Ingrid Oakley-Girvan; Gretchen Keel; Noreen M Aziz Journal: J Cancer Surviv Date: 2013-02-16 Impact factor: 4.442
Authors: Sadeer G Al-Kindi; Ghaith F Abu-Zeinah; Chang H Kim; Vittal Hejjaji; Basem M William; Paolo F Caimi; Guilherme H Oliveira Journal: Clin Lymphoma Myeloma Leuk Date: 2015-08-05
Authors: Matthew A Lunning; Shelby Kutty; Eric T Rome; Ling Li; Asif Padiyath; Fausto Loberiza; Robert Gregory Bociek; Philip J Bierman; Julie M Vose; James O Armitage; Thomas R Porter Journal: Am J Clin Oncol Date: 2015-08 Impact factor: 2.339
Authors: Noemi Pavo; Markus Raderer; Martin Hülsmann; Stephanie Neuhold; Christopher Adlbrecht; Guido Strunk; Georg Goliasch; Heinz Gisslinger; Günther G Steger; Michael Hejna; Wolfgang Köstler; Sabine Zöchbauer-Müller; Christine Marosi; Gabriela Kornek; Leo Auerbach; Sven Schneider; Bernhard Parschalk; Werner Scheithauer; Robert Pirker; Johannes Drach; Christoph Zielinski; Richard Pacher Journal: Heart Date: 2015-09-28 Impact factor: 5.994
Authors: Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli Journal: Mayo Clin Proc Date: 2014-09 Impact factor: 7.616
Authors: Raghda Ramadan; Els Vromans; Dornatien Chuo Anang; Ines Goetschalckx; Delphine Hoorelbeke; Elke Decrock; Sarah Baatout; Luc Leybaert; An Aerts Journal: Front Pharmacol Date: 2020-03-05 Impact factor: 5.810